Despite soaring global demand for healthcare, the challenge of profitably developing treatments has never been greater or more ethically complex. Can pharma giants strike the right balance?
Recent insights
29 April 2020
Commonwealth fails in its claim for compensation for PBS expenditure
23 April 2020
COVID-19: People: Contact Tracing – balancing civil liberties (Australia)
21 April 2020
COVID-19: ÁREAS DE IMPACTO: Últimas novedades en el sector farmacéutico y salud (España)
14 April 2020
Exploring Opportunities: The impact of Covid-19 on competition law in the pharmaceutical sector (Europe)
7 April 2020
COVID-19: Pressure points: Online sales of pharmaceuticals – now available? (Russia)
17 März 2020
COVID-19: Potential legal impact (Spain)
3 März 2020
A General Safety Provision - are we there yet??
3 März 2020
Directors and ESG disclosure – The risks will only get bigger
10 Februar 2020
Patent and Pharma Update, February 2020
6 Februar 2020
Australian privacy law reform and review announced
6 Februar 2020
ECJ rules for the first time on “pay-for-delay” agreements
30 Januar 2020
Unfolding privacy class actions in Australia
Key contacts
Alan Montgomery
Partner, Head of Pharmaceuticals Sector, Chair of India Group, London
Chris Parker KC
Partner, Head of Pharmaceuticals Sector, London
Natalie Bryce
Partner, Brisbane